Kornimate/medical-research-clean huggingface dataset:
prevalence study and identification of factors prognosis of obstructive sleep apnea syndrome sleep in pregnant women

Conditions: Pregnancy Related

Summary: the exact prevalence of sleep-disordered breathing in pregnant women is not known. the results of a analysis of a small cohort of 105 pregnant women adjusted to body mass index estimate a prevalence of 8.4% in first quarter and 19.7% in the third quarter. in this context, this study proposes to assess the prevalence of sleep-disordered breathing in pregnant women of the private hospital of the loire and to identify the risks associated with these disorders by systematically proposing a polysomnography.

pregnancy brings physical and hormonal changes and sleep is impaired by heartburn, cramps, frequent urination, fetal movements... snoring is commonly observed in pregnant women at the end of the second and third trimester. snoring can be a manifestation of osas. it has been shown that the apnea-hypopnea index (ahi) increases during pregnancy, at the third quarter. physiological changes associated with pregnancy increase the risk of osas. in pregnant women, sleep deprivation leads to increased risk of gestational diabetes, high blood pressure, preeclampsia and antenatal depression, but also a risk of premature delivery or having a child with a delay in growth. finally, the exact prevalence of sleep-disordered breathing in pregnant women is not known. the results of a analysis of a small cohort of 105 pregnant women adjusted to body mass index estimate a prevalence of 8.4% in first quarter and 19.7% in the third quarter. in this context, this study proposes to assess the prevalence of sleep-disordered breathing in pregnant women of the private hospital of the loire and to identify the risks associated with these disorders by systematically proposing a polysomnography.

Eligibility criteria:
inclusion criteria: * pregnant woman aged 18 and over. * pregnant woman who has not yet completed her consultation of the 1st quarter. * woman accepting the achievement of, at most, 2 polysomnographies. * affiliated participant or beneficiary of a security regime social. * participant having been informed of the study and not objecting to the use of her data. * authorization to collect and use the baby's data. exclusion criteria: * participation in another clinical study. * participant with protected status: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision. * participant hospitalized without consent
utility of 18f-rhpsma-7.3 in the diagnosis of prostate cancer after focal gland treatment

Conditions: Ability of Post-treatment PSMA-PET Scan to Detect Residual Disease

Summary: to evaluate the effectiveness of a psma-pet scan in identifying recurrent prostate cancer after focal therapy

psma is a protein that is highly expressed in prostate cancer cells, making it an excellent specific target for imaging with pet scans that can provide detailed information about the location, extent and aggressiveness of prostate cancer lesions. these scans have proven invaluable for identifying and characterizing prostate cancer, aiding in treatment planning, and monitoring treatment response. it's true and fully utility in focal therapy for prostate cancer is unknown.

Eligibility criteria:
inclusion criteria: * adult males 18 years or older; * patient must have a pre-treatment mri; * patient underwent soc focal therapy with either focal or hemiablation for the treatment of intermediate risk prostate cancer in the past 9 months prior to enrollment; * intermediate risk disease as defined by american urology academy (aua)/national comprehensive cancer network (nccn) guidelines (see appendix a) * life expectancy of 10 years or more; * underwent standard template biopsy before treatment with a minimum of 2 cores into the mri visible lesion if lesion was present; * patient understands the purpose of the trial and procedures required for the trial, and can provide signed informed consent as which includes compliances with the requirements and restrictions listed in the informed consent form (icf) and in the study protocol; and * ability to adhere to the study visit schedule and all the protocol requirements, including surveillance imaging and test specimen (blood sample) collection at specified time points. exclusion criteria: * patients under the age of 18 will be considered pediatric patients and will not be included in this study because they are thought to represent a unique population outside the scope of this study as it is aimed at identifying factors that affect adults only. * patients previously treated with whole gland ablation or prior partial gland ablation over 9 months prior to enrollment.
efficacy of insulin lispro mix 50/50 therapy

Conditions: Diabetes Mellitus, Type 2

Summary: insulin therapy with lispro mix 50/50 t.i.d. is a treatment with a single insulin device. the management is comparatively simple and easy, but the curative effect is promising. it is also reported that noninferiority has been observed between basal/bolus therapy (bbt) and prandial premixed therapy (ppt, lispro mix 50/50 t.i.d.). the purpose of this study is to evaluate whether change of insulin therapy from bbt (long-acting insulin at bedtime plus mealtime rapid-acting insulin) or analog insulin therapy t.i.d. (including therapies with aspart mix 70/30 and lispro mix 75/25) to lispro mix 50/50 t.i.d. improves glycemic control of patients with type 2 diabetes mellitus.

patients will continue existing insulin therapy for three months. after that, the investigators will change insulin therapy according to the insulin regimen below and continue the therapy for six months. patients will terminate from sulfonylurea treatment at the change of insulin therapy. the investigators will not change other oral hypoglycemic agents during the whole study period. regimen: divide the total units of all insulin per day by three and equally apply the amount to mealtime injections of insulin lispro mix 50/50 t.i.d. when the unit is indivisible and the remainder is one unit, add it to the mealtime injection of breakfast. when the remainder is two units, add each unit to mealtime injections of breakfast and dinner. patients will terminate from the trial when their hba1c increases by 1% and stays at the level for more than three months after the change of insulin regimen. when there is a risk of hypoglycemia at the change of insulin regimen, the investigators will divide ninety percent of the total insulin units per day by three and equally apply the amount to mealtime injections of insulin lispro 50/50. when considered to be safe, the investigators will increase the insulin unit per day to the total insulin unit at the previous treatment within two months.

Eligibility criteria:
inclusion criteria: type 2 diabetes patients who are treated with insulin basal/bolus therapy ( long-acting insulin at bedtime and mealtime rapid-acting insulin ) or analog insulin therapy t.i.d. (including therapies with aspart mix 70/30 and lispro mix 75/25) and whose hba1c is above 7.4%. exclusion criteria: * patients with renal failure with serum creatinine level ≧ 2.0 * patients with hepatocirrhosis * patients with proliferative diabetic retinopathy or worse * patients with acute infectious disease * patients who are treated with steroids * patients with cancer * pregnant patients * patients who are decided to be inappropriate subjects by study physicians

Keywords: insulin lispro insulin therapy hemoglobin a1c protein, human blood glucose self-monitoring quality of life hypoglycemia diabetes mellitus 1,5-anhydroglucitol
opportunistic fragility fracture risk estimates from radiographs

Conditions: Osteoporosis

Summary: the proposed study will predict a patients' risk of having osteoporosis by using a combination of the ibex bh (bone health) software outputs and other clinical risk factors such as age, gender, medical history and lifestyle. a comparison will be made between the ibex bh prediction and the one calculated in current clinical practice using a tool called frax (fracture risk assessment tool) which combines clinical risk factors with results from a dual energy x-ray absorptiometry (dxa) assessment. the study involves conducting these assessments on several new anatomies including knee, ankle and pelvis, to extend the market reach and clinical utility of ibex bh. the expected outcome of the study is that the ibex bh will offer better decision support to clinicians in terms of referral on for a dxa scan or osteoporosis investigations than available today.


Eligibility criteria:
for the collection of test data in the study. inclusion criteria: * male or female * 50 years of age or over exclusion criteria: * women who are pregnant or are breastfeeding. * participants who have sustained fractures in both hips. * unwilling or unable to provide informed consent. for the collection of healthy-normal data in the study. inclusion criteria: * male or female * 20-30 years of age exclusion criteria: * women who are pregnant or are breastfeeding. * participants who have sustained fractures in both hips. * unwilling or unable to provide informed consent.
minimally invasive hypoglossal nerve stimulation study (lingual study)

Conditions: Sleep Apnea, Obstructive

Summary: the purpose of this study is to assess the effect of transvenous hypoglossal nerve stimulation (thgns) on tongue position in the upper airway. activation of the hgn will cause contraction of the genioglossus muscle, which will move the tongue forward, opening the upper-airway and reducing apnea-hypopnea events in patients with obstructive sleep apnea (osa). a transvenous approach will be less risky and traumatic than current hgns systems that require an open surgical approach to wrap a cuff electrode around the hgn.

the primary objective is to determine the effect of thgns on tongue position in the upper airway in subjects undergoing an ep, cardiac catheterization or device procedure. (measured as changes in the anteroposterior dimensions (2-dimensional) of the retropalatal and retrolingual airway spaces.) this will be an acute study lasting no more than 45 min during a standard new device implant, cardiac catheterization and/or ep procedure. the hypoglossal nerve will be stimulated from the lingual vein using various stimulation parameters. tongue motion, upper airway opening or any side effects will be recorded. at the end of the test procedure all hardware - the catheters, lead and/or guide wire will be removed.

Eligibility criteria:
inclusion criteria: * subject is at least 18 years old * subject is undergoing a standard new device implant, cardiac catheterization involving right heart catheterization and/or ep procedures * subject is able and willing to give informed consent exclusion criteria: * subject is unable or unwilling to participate with study procedures * subject is pregnant (all women with childbearing potential must have a negative pregnancy test within 7 days prior to enrollment) * subject is known to be allergic to radio opaque dye * subject has a body mass index (bmi) \>40 kg/m2 * subject has had prior neck surgery that may interfere with vascular access to the lingual vein * subject has had prior surgery of the oral cavity that may interfere with tongue or soft palate movement * subject has a significant upper airway-related anatomic anomaly * subject is enrolled in a concurrent study that may confound the results of this study.

Keywords: sleep apnea, neural stimulation
augmentation in tx-resistant ocd: an open label trial

Conditions: Obsessive Compulsive Disorder

Summary: this study examines the use of acamprosate (campral(r)) in the treatment of obsessive compulsive disorder (ocd). the treatment of this condition is difficulty and a large percentage of patients fail to respond to medications and have residual symptoms. such patients are referred to as having treatment resistant ocd.

a patient will receive study drug for about 12 weeks. throughout the study, the study doctor, on best medical judgment, may gradually increase or decrease the dose of the study medication. the adjustments will dependent on the subject's response and whether the subject has side effects. once the subject has completed treatment under this study, the subject may resume standard treatment for his/her obsessive compulsive disorder by their regular doctor.

Eligibility criteria:
inclusion criteria: * men and women between 19-55 years of age * have dx of ocd as determined by the structured clinical interview for dsm-iv axis 1 disorders * ssri resistant patients with ocd * subjects who are able to comprehend and satisfactorily comply with protocol requirements and have ability to read and write english. * signed written informed consent prior to entering any study procedures. * concomitant psychotropic medications permitted only if prescribed at stable dose for at least 1 month before screening visit exclusion criteria: * patients with concurrent dsm-iv diagnosis of delirium, dementia, amnestic and other cognitive disorders * patients with concurrent dsm-iv diagnosis of mental retardation * patients with concurrent dsm-iv diagnosis of lifetime schizophrenia and other psychotic disorders * patients with concurrent dsm-iv diagnosis of lifetime bipolar disorder * substance dependence or abuse (excluding nicotine) within 6 months prior to screening visit * patients with score of less than 16 on y-bcos during screening. * patients with history of intolerance or hypersensitivity to acamprosate. * patients based on history or mental status exam have significant risk fo committing suicide. * patients who are homicidal or violent. * patients with severe renal impairment * female patients who are pregnant or lactating * subjects with history of psychosurgery for ocd

Keywords: obsessive compulsive disorder ocd treatment-resistant ssri
micrornas in acute kidney injury

Conditions: Kidney Injury in Cardiac Surgery - Expression of microRNAs

Summary: profiling of micrornas and long noncoding rnas (lncrnas) in patients undergoing cardiac surgery. analysis: prediction of acute kidney injury by plasma expression profile of micrornas?

in this pilot study we will include 150 patients undergoing cardiac surgery in a german university hospital. we will profile microrna expression in plasma and urine before and at several timepoints after surgery. we will use a preselected panel of micrornas and lncrnas for analysis. goal is to identify micrornas/lncrnas that are able to predict the occurence of aki in these patients.

Eligibility criteria:
inclusion criteria: * cardiac surgery exclusion criteria: * preexisting chronic kidney injury * inclusion in another study * pregnancy * kidney transplantation in history * gfr \< 30 ml/min (glomerular filtration rate) * ecls therapy (extracorporal life support)
effectiveness of subcutaneous glargine on the time to closure of the anion gap in patients presenting to the emergency department with diabetic keto-acidosis

Conditions: Diabetic Ketoacidosis

Summary: to determine if co-administration of subcutaneous (sq)insulin glargine in combination with intravenous (iv) insulin decreases the time to resolution of ketoacidosis and requirement for icu admission compared to iv insulin with delayed administration of sq glargine for the treatment of diabetic ketoacidosis (dka).


Eligibility criteria:
inclusion criteria: * age \>18 years * blood glucose \>200 * potential of hydrogen (ph) \< 7.3 * bicarbonate \< 18 * ketonemia or ketonuria * anion gap \> or = 16 exclusion criteria: * age \< 18 years * pregnant * end state renal disease (esrd) * prisoners * patients in shock or requiring emergency surgery * those unwilling to consent for the trial * allergic to insulin glargine

Keywords: diabetes mellitus diabetic ketoacidosis insulin glargine anion gap metabolic acidosis
a evaluation of biomarkers associated with sports induced concussions in college student athletes

Conditions: Traumatic Brain Injury; Sports Concussion; Sports Injury

Summary: the purpose of this study is to study the biomarkers in subjects before and after sports-induced traumatic brain injury. the assay will be studied in a sample population of subjects over the age of 18 participating in college sports.

concussion or mild traumatic brain injury (mtbi) is a condition that affects hundreds of thousands of patients worldwide. it is a biomechanically induced neurological injury, resulting in an alteration of mental status, such as confusion or amnesia, which may or may not involve a loss of consciousness. concussion affects about 1.6 million to 3.8 million athletes yearly, most commonly in contact sports such as american football and boxing. early clinical effects of concussion include but are not limited to behavioral changes, impairments of memory and attention, headache, unsteadiness, and rarely, catastrophic severe brain injury (sometimes described as second impact syndrome). more recently, the consequences of repetitive mtbi from multiple concussions in a sports setting are becoming evident. repeated concussions have been associated with greater severity of symptoms, with longer recovery time, and chronically with earlier onset of age-related memory disturbances and dementia. as a result and in contradistinction to the decades-earlier perception that these injuries were benign, sports medicine professionals are now increasingly being instructed to recognize and manage concussions as soon as they occur. "understanding the neurobiology of concussion will lead to development and validation of physiological biomarkers of this common injury." these biomarkers (e.g., laboratory tests, imaging, electrophysiology) will then allow for improved detection, better functional assessment and evidence-based return to play recommendations.

Eligibility criteria:
inclusion criteria: * the subject is a university of florida student athlete on a team participating in the study * the subject is at least 18 years of age at screening (has had their 18th birthday) * the subject is willing to undergo the informed consent process prior to enrollment into this study. * it is the principal investigator's opinion that based on the knowledge of the subject that the subject is an appropriate candidate for the study. exclusion criteria: * participating in another clinical study that may affect the results of either study. * venipuncture not feasible (i.e. skin integrity compromised at the venipuncture sites, blood vessel calcification. * not available for the end of season follow-up visit. * the subject is otherwise determined by the investigator to be medically unsuitable for participation in this study.

Keywords: traumatic brain injury sport concussion head injury sports injury
preterm premature rupture of fetal membranes: cervical ultrasound and biological markers to diagnose prematurity (rechobiol)

Conditions: Premature Rupture of Membrane

Summary: our main hypothesis is to consider that the detection of biomarkers on admission combined with the length of the cervix would improve the prediction of the latency period in case of preterm premature rupture of membranes (pprom). the primary purpose of the protocol is to assess the performance of these tests to predict a latency period \<48 hours in case of pprom.

preterm premature rupture of membranes (pprom) is defined as a spontaneous rupture before the start of labor ("premature" rupture) and before 37 weeks of gestation ("preterm"). pprom concern 2-3% of pregnancies. it is the main cause of prematurity since it is responsible for 24 to 42% of preterm deliveries. the time between prom and childbirth is named the latency period. its total duration can vary from a few hours to several weeks. childbirth occurs within 48 hours of rupture for 18 to 93% of cases, within 7 days for 56 to 96% and within 28 days for 78 to 100%. the earlier prom occurs during pregnancy, the longer the latency period is. the factors associated with a shorter latency period are: cervical changes during admission for pprom, a shortened cervix on ultrasound or a threat of premature delivery prior to prom, the existence of uterine contractions, oligoamnios, and the occurrence of a materno-fetal complication of pprom. in a pprom situation, a prolonged latency period improves the neonatal prognosis by increasing the gestational age of birth, gives the possibility of administering the corticosteroid treatment of fetal pulmonary maturation and also allows an in utero transfer in an adapted maternity. several studies have shown a correlation between the length of the cervix during rupture and the latency period in the context of pprom. to date, there are no effective biomarkers used in current practice to predict this latency period. we want to assess the diagnostic performance of different vaginal (pibf / pp14 / igfbp1 native and total) and serum (pibf / mif) markers as well as the ultrasound length of the cervix to predict the duration of this latency period in order to better anticipate the risk of prematurity.

Eligibility criteria:
inclusion criteria: * parturient admitted to the clermont-ferrand hospital maternity for preterm premature rupture of membranes between 24+0 and 36+4 gestation week. * capacity to give informed consent. * coverage by a french social security scheme. exclusion criteria: * refusal to participate * pprom formally occurred more than 24 hours ago (free flow or positive breakage test) * cervical dilatation ≥ 4 cm * multiple pregnancy * known uterine malformation * fetal malformation * placenta previa * abundant metrorrhagia * patient under guardianship or curatorship

Keywords: preterm premature rupture of membranes biomarkers latency period predictive value of tests